We are developing a robust pipeline of indications that will soon transform the treatment landscape for patients with life-threatening NET–driven diseases.
Our First-In-Man study is designed to assess the safety and efficacy of therapeutic apheresis, with our NucleoCapture device in patients with sepsis and septic shock. Establishment of clinical proof of concept in sepsis and septic shock with subsequent CE Marking will position us for rapid expansion into a series of indications with unmet medical need.
Recent studies have clearly demonstrated that the pathological chain reaction triggered by the release of NETs leads to bystander tissue damage and drives a fatal course of disease in sepsis patients. Elevated levels of NETs in blood are a hallmark of sepsis. NETs rise in the very early phase of sepsis, continue to track closely with disease progression and have predictive power for patient mortality.
Recent studies have confirmed that NETs directing cancer cell genomic instability, migration , invasion and metastasis formation. In patients with advanced cancer NETs facilitate development of thrombosis and coagulopathies, hyperinflammatory state, systemic immunosuppression and organ failures. In patients receiving anticancer treatment NET release promote spread of drug resistance and drug toxicities.
Collected clinical evidence shows that excessive formation and impaired clearance of neutrophil extracellular traps are involved in the progression of a variety of autoimmune diseases including Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis, Heparin-induced Thrombocytopenia, ANCA-associated Vasculitis and some others.